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Background: The consumption of carbapenems has increased worldwide, together with the increase in resistant
gram negative bacilli. Subsequently, the prevalence of carbapenem-resistant Acinetobacter infections has
increased rapidly and become a significant problem particularly in intensive care unit patients. The aim of the
present study was to evaluate the changes in the prevalence of Acinetobacter infection by restricting the
consumption of carbapenems in intensive care unit patients.
Methods: This study was conducted between May 1, 2011 and February 28, 2013. The amount of carbapenem
consumption and the number of patients with multi-drug resistant Acinetobacter baumannii (MDRAB) isolates
during the study period were retrospectively obtained from the records of the patients, who were hospitalized
in the intensive care unit. The study period was divided into two periods named as: Carbapenem non-restricted
period (CNRP) and carbapenem-restricted period (CRP). During CNRP, no restrictions were made on the use of
carbapenems. During CRP, the use of carbapenems was not allowed if there was an alternative to carbapenems.
Primary Endpoint: MDRAB infection after ICU admission. The definition of nosocomial infections related to
Acinetobacter spp. was based on the criteria of the Center for Disease Control (CDC). The correlation between
the amount of carbapenem consumption and the number of infections with MDRAB strains between the two
periods were evaluated.
Results: During the study period, a total of 1822 patients’ (1053 patients in CNRP and 769 patients in CRP)
records were evaluated retrospectively. A total of 10.82 defined daily dose (DDD/100 ICU days) of
anti-pseudomonal carbapenem were used in CNRP, and this figure decreased to 6.95 DDD/100 ICU days in CRP.
In the 8-month CNRP, 42 (3.98%) MDRAB-related nosocomial infections were detected, and 14 (1.82%) infections
were detected in CRP (p = 0.012).
Conclusion: The prevalence of MDRAB strains isolated in the CNRP was 2.24-fold higher than the prevalence in
the CRP. The prevalence of Acinetobacter infections can be reduced by taking strict isolation measures as well as
by implementing good antibiotics usage policy.
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Nosocomial infections (NI) caused by multidrug-resistant
gram negative bacilli have become a significant problem
in recent years [1]. Micro-organisms isolated from NI
vary depending on the changes in antibiotic usage po-
licy. Acinetobacter spp. has an important place among
the causes of NI [2].
Acinetobacter spp. rarely causes infections in a normal
host due to their low virulence. However, this agent is the
most important cause of infections in intensive care units
(ICUs). Acinetobacter spp. cannot be totally eliminated
from intensive care units despite numerous established in-
fection control measures. NIs caused by Acinetobacter
spp. are associated with morbidity and mortality, and lead
to increases in the length of hospital stay, as well as in
treatment costs [3]. Acinetobacter spp. remains viable for a
long period of time in a hospital setting, and can be iso-
lated from soil, water, and food. The bacteria can colonize
in healthy individuals and in hospitalized patients [4]. One
of the most important factors that play a role in the spread
of Acinetobacter spp. is the ability of bacteria to easily de-
velop resistance to antibiotics. In the 1990s, most Acineto-
bacter spp. was sensitive to quinolones and carbapenems.
However, hospital outbreaks caused by multiple-drug-
resistant Acinetobacter baumannii (MDRAB) are reported
in many countries in the last 10 years [5]. The infection
with resistant strains was associated with higher mortality
rates, longer hospital stays, and higher treatment costs [6].
In order to develop a common language for the resist-
ance problem, bacteria resistant to ≥3 antibiotics are called
multi-drug resistant (MDR) bacteria, and those resistant
to all antibiotics are called pan-resistant bacteria [7]. The
most important risk factor for the infections caused by
MDR strains is the previous use of broad spectrum anti-
biotics [8]. Carbapenems are the most effective antibiotics
in the treatment of infections caused by resistant strains
of Acinetobacter spp [9]. However, carbapenem-resistant
Acinetobacter strains are increasing worldwide [2]. Previ-
ous studies have reported infection and/or colonization of
carbapenem-resistant Acinetobacter baumannii as the in-
dependent predictor of previous use of carbapenems
[10-12]. Moreover, undesired affects in bacterial ecology
occurring as the result of antibiotic therapy are called col-
lateral damage (CD). CD implies antibiotic-resistant bac-
teria, multi-drug resistant bacteria, and infections and
colonization by Clostridium difficile [13,14]. Antimicrobial
agents used for treatment purposes cause CD by affecting
not only the infectious agent but also microflora. CD is
more frequently pronounced with the use of broad
spectrum antibiotics in the hospital setting. The selection
rate of the resistant bacteria varies depending on the type
of antibiotics administered. Antibiotics most commonly
associated with CD include third generation cephalospo-
rins, fluoroquinolones, and carbapenems [14,15].Can restriction of the use of carbapenems, which are ef-
fective against Acinetobacter spp, result in a change in the
prevalence of MDRAB? There are limited studies address-
ing this question. The present study was aimed to evaluate
changes in the prevalence of MDRAB-related infections
with the restriction of the use of carbapenems.
Methods
Study design and data collection
The present study was conducted in a 550-bed tertiary
care hospital in Marmara region, Sakarya (Turkey),
retrospectively. We evaluated the medical records of pa-
tients who were hospitalized in the intensive care units
of Sakarya University Training and Research Hospital
(STRH) from May 1, 2011 to February 28, 2013. There
were 24 beds in ICUs in the study periods. The bed ca-
pacity was the same in the both periods. The average of
1360 ICU patients were followed over the last four years
in ICUs (1141, 1305, 1356, and 1403 respectively). Both
surgical and internal patients who need intensive care
were followed in the general ICU. Neurological patients
were followed in the neurology ICU. Patient characteris-
tics were similar in the periods. Reanimation specialist was
followed the patients in the general ICU. Neurologist was
followed the patients in the neurology ICU. Infectious
diseases specialists were consulted ICUs every day. The
amount of carbapenem consumption and data relevant
to isolated MDRAB strains were obtained from the
medical charts.
Study periods
The study was conducted in two periods
Carbapenem non-restricted period (CNRP) and carbapenem-
restricted period (CRP).
CNRP
Between May 1, 2011 and February 28, 2012. During this
period, consulting physicians from the department of infec-
tious diseases (CP) used carbapenem without any restric-
tion in conditions they deemed appropriate. Carbapenem
was not prescribed unless approved by the CP.CRP
Between May 1, 2012 and February 28, 2013. The carba-
penem usage was restricted during this period in the
presence of an alternative therapy. The approval of the
director of the department was sought for the use of
carbapenem. Other CPs preferred alternative options
other than carbapenem. During the carbapenem-restricted
period, other options including piperacillin-tazobactam,
cefoperazone-sulbactam, cefepime, tigecycline, and colistin
were allowed. No restriction was allowed if the strain was
sensitive only to carbapenems.
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Normally, all of the specialists could prescribe all anti-
biotics except 15 ones that required approvement by the
infectious diseases specialist. MDRAB isolations were in-
creased despite all of the infection control measurements.
Moreover the Acinetobacter baumannii isolations were
not susceptible to any drug except colistin. Some patients
treatment were failed due to MDRAB infections. We
searched the literatures, and then we decided to carba-
penem restriction according to directives of infection con-
trol committee chairman. After the CNRP, we explained
the carbapenem restriction and restriction requirement to
the doctors. We did not do anything except carbapenem
restriction.
Primary end-point
MDRAB infection occurring after admission to the
intensive care unit.
MDRAB case definition
Patients from whom MDRAB was isolated and who
were administered with carbapenem or other therapies
for ≥ 72 hours during CNRP and CRP.
Inclusion criteria
Patients from whom MDR bacteria was isolated and
who were diagnosed with systemic infection or
pneumonia, and catheter, urinary tract, and wound site










































Figure 1 Distrubition of the isolated microorganisms in the study perinfection, pneumonia, urinary tract, catheter, or wound
site infection was made according to the criteria of the
CDC [16]).
Patients falling under the scope of item one and who
received carbapenem or other therapy for at least
72 hours.
Exclusion criteria
Sensitive strains that did not meet MDR criteria.
Patients with missing data.
Patients who were considered to be colonization.
Patients in whom carbapenems are contraindicated.
Pregnant women.
Patients below the age of 18 years.
Multi-Drug Resistance (MDR)
Acquired non-susceptibility to at least one agent in three or
more antimicrobial categories (ampicillin/sulbactam,
aztreonam, ceftazidime, ciprofloxacin, gentamicin, imipe-
nem, piperacillin-tazobactam and trimethoprim/sulfame-
thoxazole) or resistance to >1 agent in ≥3 different groups
of antibacterial including carbapenems [17].
Statistical analysis
Epi-info (CDC, Atlanta, USA) 6.0 software was used in
the statistical analysis. P values <0.05 were considered
significant.
The study was designed as a retrospective study. There-






































Number of patients with




No 1053 (57,7) 42 (3,9) 2.24 (1.18-4.33) 0.012
Yes 769 (42,2) 14 (1,8)
Total 1822 56 (3,0)
Ogutlu et al. Annals of Clinical Microbiology and Antimicrobials 2014, 13:7 Page 4 of 6
http://www.ann-clinmicrob.com/content/13/1/7Results
During the study period, a retrospective review of the re-
cords of 1822 patients (1053 patients (57.85) in CNRP
and 769 (42.2%) patients in CRP) was evaluated. Carba-
penem consumption was described as DDD/100 ICU days
by months (Figure 1). A total of 10.82 defined daily dose
(DDD/100 ICU days) of anti-pseudomonal carbapenem
were used in CNRP, and this figure decreased to 6.95
DDD/100 ICU days in CRP. There was also an increase in
the number of ertapenem (0.32 DDD/100 ICU days/0.76
DDD/100 ICU days) and amikacin (0.49 DDD/100ICU
days/0.65 DDD/100 ICU days). During the study, MDRAB
were isolated in total of 56 (3.1%) patients. MDRAB were
isolated from 42 patients (3.98%) in CNRP, and from 14
patients (1.82%) in CRP (p = 0.012). The prevalence of
MDRAB strains isolated in the CNRP was 2.24-fold higher
than the prevalence in the CRP (Table 1). While Pseudo-
monas aeruginosa isolations were increased in the CRP,
Staphylococcus aureus isolations were decreased (Figure 2).
Nosocomial infection density was 8.75 for 1000 patient
days in CRP while nosocomial infection density was
19.70 in CNRP.
Discussion
This study showed that the restriction of carbapenems in
the intensive care units would cause a 2.24-fold reduction
in the prevalence of MDRAB infections (p = 0.012). Ac-
cordingly, strictly restricting carbapenems in intensive care
















































































































Carbapenem consumption and MDR-Acinetobacter bauman
Figure 2 Carbapenem consumption and MDR-Acinetobacter baumanAnti-pseudomonal carbapenems are the choice of first
line drugs in the treatment of infections by Acinetobac-
ter spp. MDRAB strains are rapidly increasing due to
the inappropriate use of carbapenems and other broad
spectrum antibiotics. A 77% resistant rate has been re-
ported in Acinetobacter strains isolated from ICU pa-
tients in 2012, in Turkey [18]. Therefore, carbapenems
may not be the first choice in the ICU in Turkey. Un-
controlled consumption is one of the most important
factors that rendered carbapenems useless in the treat-
ment of Acinetobacter infections [19]. While depleting
antibiotic arsenal for use in infections caused by resis-
tant bacteria, further strategies need to be implemented
to maintain the effectiveness of current antibiotics for
longer duration in clinical use.
The prevalence of resistant Acinetobacter strains are
higher in countries such as Greece, Turkey, and Italy,
where carbapenems are intensely used, and the prevalence
is lower in countries such as Holland, and Scandinavian
countries [20,21].
Anti-microbial agents cause CD by not only affecting
the infectious agent, but also affecting the micro flora of
the hospital. The selection rate of the resistant bacteria
varies depending on the type of antibiotics employed.
Compared to other broad spectrum antibiotics, carbapen-
ems also increase the colonization of MDR-Acinetobacter,
MDR-Pseudomonas aeruginosa, carbapenemase-positive
Klebsiella and C.difficile through CD [15,22]. In the
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tibiotics most commonly associated with CD include third
generation cephalosporins, fluoroquinolones, and carba-
penems [14,15]. In the present study, we think that lower
prevalence of Acinetobacter infections in the CRP was due
to the change in normal micro flora in the hospital.
In the literature, the studies suggest previous carba-
penem consumption as a risk factor for MDR-Acinetobac-
ter infections [23-25]. Our study results showed that all the
microorganism isolations were decreased except Staphylo-
coccus aureus in the CRP. A positive correlation was ob-
served with anti-pseudomonal carbapenem (imipenem and
meropenem) consumption and the development of resist-
ance in Acinetobacter and Pseudomonas in a study which
made in India [3]. MDRAB infections were shown to in-
crease 16 times by using antipseudomonal carbapenems in
a study conducted in Taiwan (19). Moreover, this increased
resistance was not shown in any antimicrobial group ex-
cept carbapenem. In this study, the importance of restric-
tion in the use of antipseudomonal carbapenems was
emphasized for the decreasing and controling of the
MDR-Acinetobacter infection [19]. This situation may be
due to selection of MDR-Acinetobacter which could be
become resistant easly with broad-spectrum antibiotics
such as carbapenems. We also think the requirements
of rational antibiotic use policies for reduce the spread
of MDR-Acinetobacter spp .
One study showed a significant reduction in the isola-
tion of MDR-Acinetobacter strains in association with car-
bapenem restriction [26]. However, antibiotic stewardship
programs alone are not sufficient to prevent Acinetobacter
infections. Hand hygiene and other isolation measures are
as important as antibiotic management.
Before any conclusion we should declare limitations of
our study. This study was done only with a limited num-
ber of cases in a single center. If the number of cases were
much more, study could has been more power. If we
could be watched the genotypic changes in the bacterial
resistance between the study periods, our results could
have been more effective.
In conclusion, the strict restriction of carbapenem use is
an important strategy to reduce the prevalence of MDR-
Acinetobacter strains. However, all precautions (i.e. barrier
measures, hand washing, sterilization, and disinfection)
should be taken in intensive care units with the goal of
achieving a "0%" infection rate.
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